[Lymphadenectomy in gastric carcinoma?]

Area of Science:

• Surgical Oncology
• Gastroenterology
• Pathology

Background:

• The role of lymphadenectomy in gastric carcinoma management remains a subject of ongoing discussion.
• D2-lymphadenectomy, a comprehensive lymph node dissection, is primarily indicated for R0 resections based on existing studies.

Purpose of the Study:

• To evaluate the indications and survival benefits of D2-lymphadenectomy in gastric carcinoma.
• To assess the prognostic value of pathological data obtained from D2-lymphadenectomy specimens.

Main Methods:

• Review of non-randomized and randomized studies on lymphadenectomy in gastric cancer.
• Analysis of patient subgroups benefiting from D2-lymphadenectomy, including nodal involvement and lymph node ratio.
• Consideration of the technical demands and potential complications of D2-lymphadenectomy.

Main Results:

• Survival advantages are observed in patients with limited nodal involvement, favorable lymph node ratios, and stage II gastric cancer.
• An estimated 15-20% survival improvement is expected in R0 resections following D2-lymphadenectomy.
• D2-lymphadenectomy provides essential prognostic parameters, even with limited survival gains.

Conclusions:

• D2-lymphadenectomy should be performed in all R0 gastric cancer resections to obtain reliable prognostic information.
• The technique demands significant surgical experience and careful management of postoperative complications.
• Future research on sentinel lymphadenectomy may refine indications for D2-lymphadenectomy in gastric carcinoma.